New drug combo shows promise for Hard-to-Treat stomach cancer

NCT ID NCT07559864

Recruiting now Disease control Sponsor: Jian Li Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs—regorafenib (a targeted therapy) and envafolimab (an immunotherapy)—can help people with advanced GIST that has a specific gene change (KIT exon 17 mutation) and has stopped responding to standard treatments. About 100 adults will be randomly assigned to receive either the combination or the doctor's choice of other treatments. The main goal is to see how long the cancer stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GIST - GASTROINTESTINAL STROMAL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastrointestinal stromal tumor piebaldism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GIST - GASTROINTESTINAL STROMAL TUMOR KIT GENE MUTATION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100101, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact